Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law FDA to weigh easing limits on unproven peptides promoted by RFK Jr. FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for